NCT04867642View on ClinicalTrials.gov

A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

April 29, 2021

Primary Completion Date

February 27, 2023

Study Completion Date

February 27, 2023

Conditions
Healthy Study ParticipantsParkinson's Disease
Interventions
DRUG

UCB0022

Study participants will receive doses of UCB0022 in a pre-specified sequence during the Treatment Period of Part A, B and C.

OTHER

Placebo

Study participants will receive placebo comparator in a pre-specified sequence during the Treatment Period of Part A, B and C.

Trial Locations (1)

Unknown

Up0091 001, London

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY